Video

Dr. El-Khoueiry on Immunotherapy Combinations in HCC

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses immunotherapy combination in hepatocellular carcinoma (HCC).

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses immunotherapy combination in hepatocellular carcinoma (HCC).

There are several combinations of immuno-oncology (IO) agents plus other IO agents under investigation. One of the most promising combinations is PD-1/L1 inhibition with CTLA-4 inhibition. Additionally, there is the phase III HIMALAYA trial, which is combining durvalumab (Imfinzi) and tremelimumab versus durvalumab alone versus sorafenib (Sutent) in the frontline setting. Furthermore, data from a phase II cohort of nivolumab (Opdivo) plus ipilimumab (Yervoy) are anticipated.

There is also rationale to combine PD-1 inhibitors with anti-VEGF targeted therapies, says El-Khoueiry. For example, the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima), which has shown a promising early signal. There are also combinations of nivolumab and sorafenib as well as nivolumab and lenvatinib in ongoing trials. The combination of atezolizumab (Tecentriq) with bevacizumab (Avastin) is also worth mentioning, adds El-Khoueiry, as this combination has shown an objective response rate (ORR) of approximately 30%. Investigators are still working to determine whether the toxicity of these combinations is tolerable and whether the improvement in ORR will translate to improved overall survival.

Related Videos
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS
Rona Yaeger, MD
 PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Robert
Charles B. Nguyen, MD
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC